Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF GIVINOSTAT IN NON-AMBULANT PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY

Intervention/treatment:
GIVINOSTAT (ITF2357)
Medical condition:
DUCHENNE MUSCULAR DYSTROPHY
Protocol code:
DSC/14/2357/50
Control number:
277453
Status:
Recruiting
Approved:
August 15, 2023
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT05933057
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: MALE
Age
9 Years to 17 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Italfarmaco Patient Advocacy
Role
CONTACT
Phone:
+39 02 6443 1
Sponsor
ITALFARMACO S.P.A.

Locations

British Columbia

British Columbia Children's Hospital
Vancouver, British Columbia, V6H 3V4
Recruiting
Role
CONTACT
Phone:
604-875-2345
Extension 6549
Name
Kathryn Selby, MD
Role
PRINCIPAL_INVESTIGATOR

Ontario

The University of Western Ontario - Children's Health Research Institute
London, Ontario, N6A 5W9
Recruiting
Role
CONTACT
Phone:
+1 519-685-8441
Name
Craig Campbell, MD
Role
PRINCIPAL_INVESTIGATOR
University of Ottawa - Children's Hospital of Eastern Ontario
Ottawa, Ontario, K1H 8L1
Recruiting
Role
CONTACT
Phone:
+1 613-737-7600
Extension 4017
Name
Hugh McMillan, MD
Role
PRINCIPAL_INVESTIGATOR
University of Toronto - Holland Bloorview Kids Rehabilitation Hospital
Toronto, Ontario, M4G 1R8
Recruiting
Role
CONTACT
Name
Laura McAdam, MD
Role
PRINCIPAL_INVESTIGATOR
Did you find what you were looking for?